FDA Inspection 1232732 — Regeneron Pharmaceuticals Inc
The FDA completed an inspection of Regeneron Pharmaceuticals Inc on May 1, 2024 in Tarrytown, NY. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- May 1, 2024
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Tarrytown, NY (United States)
Additional Details
Sponsor, Contract Research Organization